Inclusion Criteria:

1. Patients with haematological malignancies, according to WHO classification, such as:

- acute myeloid leukaemia -AML- in CR1 except "low-risk cases" defined by
t(15;17), t(8;21), inv 16 or normal cytogenetics at diagnosis with FLT3-ITD
negative and NPM-1 positive, with no high risk clinical criteria

- any AML beyond CR1

- acute lymphoblast leukaemia -ALL- in CR1 only if at "high risk" defined by
cytogenetics as t(9;22), t(4;11) or for persistence of minimal residual disease
(MRD)

- any ALL beyond CR1

- chronic myeloid leukaemia -CML- in chronic phase (CP) or accelerated phase (AP)
intolerant/not responsive to TK-inhibitors

- myeloproliferative disorders -MPD-

- myelodysplastic syndrome -MDS- with intermediate or high risk International
Prognostic Scoring System (IPSS)

- diffuse large cell lymphoma -DLCL- with a chemosensitive relapse or beyond CR1

- lymphoblastic and Burkitt lymphoma with a chemosensitive relapse or beyond CR1

- mantle cell lymphoma -MCL- with a chemosensitive relapse or beyond CR1

- follicular lymphoma -FCL- with a chemosensitive relapse or beyond CR2

- Hodgkin lymphoma -HD- with a chemosensitive relapse or beyond CR1

- chronic lymphocytic leukaemia -CLL- at "poor risk" in CR1 or with a
chemosensitive relapse

- CLL relapsing after high dose chemotherapy

- T-cell non Hodgkin lymphoma -T-NHL- in CR1 or beyond

- multiple myeloma -MM- at high risk for cytogenetics or ISS stage 3 in CR1
following high dose chemotherapy

- MM at any relapse/progression except refractory disease

2. Availability of an HLA-identical sibling donor (MRD) or HLA-identical unrelated donor
(MUD)

- HLA-identity defined by the following markers: A, B, DRB1, DQB1 or a single or
double Cord Blood unit (CB) with at least a 4 out of 6 HLA-matching by the
following markers: A, B and DRB.

A) identity between the 2 CB units and the recipient;

B) Two identical CB units with one or two mismatches with the recipient;

C) Two CB units with one mismatch between them and two mismatches with the recipient.
We will prefer mismatches either for class I or for class II antigens; we will avoid
mismatches concerning both classes I and II together.

3. Target graft size (unmanipulated, preferably not cryopreserved)

- bone marrow: 2 to 10 x 106 CD34+ cells/kg BW recipient or > 2 x 108 nucleated
cells/kg BW recipient or

- peripheral blood: 4 to 10 x 106 CD34+ cells/kg BW recipient

4. Age > 18 and < 70 years

5. Karnofsky Index > 80 %

6. Adequate contraception in female patients of child-bearing potential

7. Written informed consent

Exclusion Criteria:

1. Secondary malignancies

2. Previous allogeneic transplantation

3. Hematopoietic cell transplantation-specific comorbidity index > 4 (HCT-CI Sorror et
al, Appendix M)

4. Known and manifested malignant involvement of the CNS

5. Active infectious disease

6. HIV- positivity or active hepatitis infection

7. Impaired liver function (Bilirubin > upper normal limit; Transaminases > 3.0 x upper
normal limit)

8. Impaired renal function (Creatinine-clearance < 60 ml/min; Serum Creatinine > 1.5 x
upper normal limit).

9. Pleural effusion or ascites > 1.0 L

10. Pregnancy or lactation

11. Known hypersensitivity to treosulfan and/or fludarabine

12. Participation in another experimental drug trial within 4 weeks before day -6

13. Non-co-operative behaviour or non-compliance

14. Psychiatric diseases or conditions that might impair the ability to give informed
consent